Linked Life Data

21419770

Source:http://linkedlifedata.com/resource/pubmed/id/21419770

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2011-6-6
pubmed:databankReference
pubmed:abstractText
Several studies have reported that low doses of interferon can delay the development of hepatocellular carcinoma (HCC) and progression of chronic hepatitis C. We investigated the incidence of clinical events among participants of the Evaluation of PegIntron in Control of Hepatitis C Cirrhosis (EPIC)3 program.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1528-0012
pubmed:author
pubmed:copyrightInfo
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
140
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1990-9
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:21419770-Antiviral Agents, pubmed-meshheading:21419770-Biological Markers, pubmed-meshheading:21419770-Carcinoma, Hepatocellular, pubmed-meshheading:21419770-Disease Progression, pubmed-meshheading:21419770-Drug Administration Schedule, pubmed-meshheading:21419770-Europe, pubmed-meshheading:21419770-Female, pubmed-meshheading:21419770-Hepacivirus, pubmed-meshheading:21419770-Hepatitis C, Chronic, pubmed-meshheading:21419770-Humans, pubmed-meshheading:21419770-Hypertension, Portal, pubmed-meshheading:21419770-Interferon-alpha, pubmed-meshheading:21419770-Kaplan-Meier Estimate, pubmed-meshheading:21419770-Liver Cirrhosis, pubmed-meshheading:21419770-Liver Neoplasms, pubmed-meshheading:21419770-Male, pubmed-meshheading:21419770-Middle Aged, pubmed-meshheading:21419770-North America, pubmed-meshheading:21419770-Patient Selection, pubmed-meshheading:21419770-Polyethylene Glycols, pubmed-meshheading:21419770-Proportional Hazards Models, pubmed-meshheading:21419770-Prospective Studies, pubmed-meshheading:21419770-RNA, Viral, pubmed-meshheading:21419770-Recombinant Proteins, pubmed-meshheading:21419770-Risk Assessment, pubmed-meshheading:21419770-Risk Factors, pubmed-meshheading:21419770-South America, pubmed-meshheading:21419770-Time Factors, pubmed-meshheading:21419770-Treatment Outcome, pubmed-meshheading:21419770-Viral Load
pubmed:year
2011
pubmed:articleTitle
Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.
pubmed:affiliation
BCLC Group, Liver Unit, Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Hepatología y Enfermedades Digestivas, Barcelona, Spain. jbruix@clinic.ub.es
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study